Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 4 2Phase NA 1Phase 2/3 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 3Neoplasms 2NSCLC 2Lymphoma, Non-Hodgkin 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Solid Tumor Regardless of Localization and Stage 1Patient Acceptance of Health Care 1Pancreatic Neoplasms 1Pain 1Oropharyngeal Neoplasms 1Neoplasms, Second Primary 1Multiple Myeloma 1Lymphoma, Extranodal NK-T-Cell 1Localized Advanced Rectal Adenocarcinoma 1Liver Neoplasms 1HER-2 Negative Breast Cancer 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Acute Kidney Injury 1

Interventions

icotinib 2anlotinib 2Drug Therapy 2lorlatinib 1Thalidomide 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × NSCLC × Drug Therapy × Clear all
NCT06893354 2025-03-25

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

The First Affiliated Hospital of Guangzhou Medical University

Phase 4 Not yet recruiting
20 enrolled
Thoracic

NSCLC

NCT03986528 2021-02-23

Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Phase 4 Unknown
334 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡